VFP-26217-30011
3 vaccinations
3 coded responses
31 check-ins
2 free-text entries
2 call cases
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 200 / DC
- Registered
- 2022-06-26
- Relationship
- Child or adolescent in my care
- Guardian
- TJ5-20934-65170
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-06-22
Dose 1 — Moderna
-
2022-06-26
Registered in v-safe
-
2022-06-26
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Good · Site: Swelling/hardness · NoneUnder 3 check-in
- 2022-06-27
- 2022-06-28
- 2022-06-29
- 2022-07-06
- 2022-07-13
-
2022-07-20
Dose 2 — Moderna
- 2022-07-20
- 2022-07-21
- 2022-07-22
- 2022-07-23
- 2022-07-24
- 2022-07-25
- 2022-07-26
- 2022-07-27
-
2022-08-03
Survey response — day 14, dose 2, under 3MedDRA: Cough, Nasal congestion, Pyrexia — Feeling: Poor · Be unable to work or attend schoolFree text: Fever, stuffy nose, coughMedDRA releases: 2024-11 · check-in free text available
- 2022-08-10
- 2022-08-17
- 2022-08-24
- 2022-08-31
-
2022-10-19
Survey response — 3 months, dose 2, under 3MedDRA: Nasopharyngitis, Respiratory syncytial virus infection — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: continuous cold symptoms. RSV A and BMedDRA releases: 2024-11 · check-in free text available
-
2022-10-19
Report sent to call center — 3 months, dose 2, under 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-10-20
-
2022-10-21
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2023-01-18
Survey response — 6 months, dose 2, under 3MedDRA: COVID-19, Respiratory syncytial virus infection — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-01-18
Report sent to call center — 6 months, dose 2, under 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2023-01-19
-
2023-03-18
Dose 3 — Moderna
- 2023-03-22
- 2023-03-23
-
2023-03-24
Health check-in — days 1–6 daily, dose 3, under 3Feeling: Fair · Sleepiness, Rash, not including the immediate area around the injection siteUnder 3 check-in
- 2023-03-25
- 2023-04-01
- 2023-04-08
- 2023-04-17
- 2023-04-22
- 2023-04-29
- 2023-06-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-06-22 | Moderna | No |
| 2 | 2022-07-20 | Moderna | No |
| 3 | 2023-03-18 | Moderna | No |
Call center
2 call center cases
1 successful · 1 unsuccessful
Free text
Release 12 (Under 3) — day 14, dose 2, under 3
Symptoms: Fever, stuffy nose, cough
Release 12 (Under 3) — 3 months, dose 2, under 3
Symptoms: continuous cold symptoms. RSV A and B
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Nasal congestion | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Respiratory syncytial virus infection | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release